Matthew Taylor
Stock Analyst at Jefferies
(3.28)
# 986
Out of 4,784 analysts
177
Total ratings
59.09%
Success rate
8.81%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $80.01 | +28.73% | 2 | Jan 8, 2025 | |
| ABT Abbott Laboratories | Maintains: Hold | $120 → $125 | $130.82 | -4.45% | 12 | Oct 17, 2024 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $70.91 | -1.28% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $258.75 | -13.82% | 14 | Aug 9, 2024 | |
| INMD InMode | Downgrades: Hold | $21 → $19 | $17.70 | +7.34% | 6 | Jul 23, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $87.63 | -13.27% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $3.20 | +3,806.25% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $163.55 | -26.02% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $4.40 | +218.18% | 1 | Jan 19, 2024 | |
| TNDM Tandem Diabetes Care | Maintains: Buy | $47 → $45 | $19.28 | +133.40% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.68 | -25.98% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $21.69 | +144.35% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $11.52 | +108.33% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $364.50 | -5.35% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $112.26 | +15.80% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $267.56 | -14.04% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $14.04 | +42.45% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $58.85 | +44.44% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $72.55 | +3.38% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $219.94 | +11.39% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $33.75 | +83.70% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $137.80 | +52.39% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $10.19 | +17.76% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $67.74 | +84.53% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $99.36 | -49.68% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $491.84 | -57.30% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $31 | $5.84 | +430.82% | 5 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $39.13 | +145.34% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $2.37 | +195.36% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $227.50 | +16.92% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $9.50 | +68.42% | 2 | Jul 19, 2017 |
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $80.01
Upside: +28.73%
Abbott Laboratories
Oct 17, 2024
Maintains: Hold
Price Target: $120 → $125
Current: $130.82
Upside: -4.45%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $70.91
Upside: -1.28%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $258.75
Upside: -13.82%
InMode
Jul 23, 2024
Downgrades: Hold
Price Target: $21 → $19
Current: $17.70
Upside: +7.34%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $87.63
Upside: -13.27%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $3.20
Upside: +3,806.25%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $163.55
Upside: -26.02%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $4.40
Upside: +218.18%
Tandem Diabetes Care
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $19.28
Upside: +133.40%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.68
Upside: -25.98%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $21.69
Upside: +144.35%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $11.52
Upside: +108.33%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $364.50
Upside: -5.35%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $112.26
Upside: +15.80%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $267.56
Upside: -14.04%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $14.04
Upside: +42.45%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $58.85
Upside: +44.44%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $72.55
Upside: +3.38%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $219.94
Upside: +11.39%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $33.75
Upside: +83.70%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $137.80
Upside: +52.39%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $10.19
Upside: +17.76%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $67.74
Upside: +84.53%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $99.36
Upside: -49.68%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $491.84
Upside: -57.30%
Oct 12, 2022
Initiates: Underperform
Price Target: $31
Current: $5.84
Upside: +430.82%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $39.13
Upside: +145.34%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $2.37
Upside: +195.36%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $227.50
Upside: +16.92%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $9.50
Upside: +68.42%